Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

Phase 2

1(20.0%)

5Total

N/A(2)

Phase 1(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01893996Phase 4Completed

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

Role: collaborator

NCT02078375Not ApplicableTerminated

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

Role: collaborator

NCT00418587Phase 1Completed

Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT00522002Completed

CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study

Role: collaborator

NCT00515008Not ApplicableCompleted

Tai Chi Mind-Body Therapy for Fibromyalgia

Role: collaborator

NCT00800254Phase 2Completed

Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement

Role: collaborator

All 6 trials loaded